Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - metastatic


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5005
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations

Joaquin Mateo · Nuria Porta · U. McGovern · Tony Elliott · Robert Jones · Isabel Syndikus · Christy Ralph · Suneil Jain · Mohini Varughese · O. Parikh · Simon J. Crabb · Susana Miranda · George Seed · Claudia Bertan · Aude Espinasse · Peter Chatfield · Diletta Bianchini · Emma Hall · Suzanne Carreira · Johann S. de Bono ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.1005
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert Hugh Jones · Margherita Carucci · Angela C. Casbard · Rachel Butler · Fouad S Alchami · Catherine Jane Bale · Pavel Bezecny · Johnathan Joffe · Sarah Moon · Chris Twelves · Ramachandran Venkitaraman · Simon Waters · Sacha J Howell ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9000
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.549
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

Funda Meric-Bernstam · Richard J. Lee · Bradley Curtis Carthon · Othon Iliopoulos · James W. Mier · Manish R. Patel · Nizar M. Tannir · Taofeek K. Owonikoko · Naomi B. Haas · Martin H. Voss · James J. Harding · Ramaprasad Srinivasan · Geoffrey I. Shapiro · Melinda L. Telli · Pamela N. Munster · Richard D. Carvajal · Yonchu Jenkins · Samuel H. Whiting · Johanna C. Bendell · Todd Michael Bauer ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9526
Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

Alexander Guminski · Annette M. Lim · Nikhil I. Khushalani · Chrysalyne D. Schmults · Leonel F. Hernandez-Aya · Badri Modi · Lara Dunn · Brett G. M. Hughes · Anne Lynn S. Chang · Axel Hauschild · Michael R. Migden · Ralf Gutzmer · Murad Alam · Vladimir Jankovic · Elizabeth Stankevich · Jocelyn Booth · S Li · Israel Lowy · Matthew G. Fury · Danny Rischin ·

Medicine
PDF

Highly Related Keywords from metastatic

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals